Vazyme(SH:688105) Xin Lang Cai Jing·2025-09-26 01:33Core Insights - NuoVance Biotechnology Co., Ltd. has experienced a decline in revenue and net profit for the first half of 2025, with a revenue of 606 million yuan, down 6.63% year-on-year, and a net profit of 3.13 million yuan, down 80.63% year-on-year [2] Group 1: Company Overview - NuoVance was established on March 16, 2012, and went public on November 15, 2021 [2] - The company focuses on the research and development of functional proteins and high molecular organic materials, with its main business segments including biological reagents (81.86%), diagnostic reagents (9.99%), consumables (3.15%), equipment (2.96%), technical services (1.85%), and others (0.18%) [2] - As of June 30, the number of shareholders increased by 2.37% to 8,596, while the average circulating shares per person decreased by 2.31% to 46,269 shares [2] Group 2: Financial Performance - For the first half of 2025, NuoVance reported a revenue of 606 million yuan, a decrease of 6.63% compared to the previous year, and a net profit of 3.13 million yuan, which is a significant drop of 80.63% year-on-year [2] - The company has distributed a total of 731 million yuan in dividends since its A-share listing, with 611 million yuan distributed over the past three years [3] Group 3: Market Activity - On September 25, NuoVance's stock price increased by 0.09%, with a trading volume of 66.34 million yuan [1] - The financing buy-in amount for NuoVance on the same day was 4.45 million yuan, while the financing repayment was 5.28 million yuan, resulting in a net financing outflow of 835,200 yuan [1] - The total balance of margin trading for NuoVance reached 101 million yuan, with the financing balance accounting for 1.11% of the circulating market value, indicating a high level compared to the past year [1]